1.Correlation between TSH Receptor Antibody Assays and Clinical Manifestations of Graves' Orbitopathy.
Sun Young JANG ; Dong Yeob SHIN ; Eun Jig LEE ; Young Joon CHOI ; Sang Yeul LEE ; Jin Sook YOON
Yonsei Medical Journal 2013;54(4):1033-1039
PURPOSE: To investigate an association between the levels of serum thyroid-stimulating hormone (TSH)-receptor autoantibodies (TRAbs) and Graves' orbitopathy (GO) activity/severity scores, and compare the performance of three different TRAb assays in assessing the clinical manifestations of GO. MATERIALS AND METHODS: Cross-sectional study. Medical records of 155 patients diagnosed with GO between January 2008 and December 2010 were reviewed. GO activity was assessed by clinical activity score (CAS) and severity graded with the modified NOSPECS score by a single observer. Serum TRAb was measured by three different methods: 1st generation thyrotropin-binding inhibitor immunoglobulin (TBII) assay (TRAb1st); 3rd generation TBII assay (TRAb3rd); and biological quantitative assay of thyroid-stimulating immunoglobulin (TSI) using Mc4-CHO cells (Mc4-CHO TSI assay). Results were correlated with scores of activity/severity of thyroid eye disease. RESULTS: All three assays (TRAb1st, TRAb3rd, and Mc4-CHO TSI) yielded results that were significantly positively correlated with CAS (beta=0.21, 0.21, and 0.46, respectively; p<0.05) and proptosis (beta=0.38, 0.34, and 0.33, respectively; p<0.05). Mc4-CHO TSI bioassay results were significantly positively correlated with all GO severity indices (soft tissue involvement, proptosis, extraocular muscle involvement, and total eye score; beta=0.31, 0.33, 0.25, and 0.39, respectively; p<0.05). CONCLUSION: Mc4-CHO TSI bioassay was superior over the two TBIIs in assessing active inflammation and muscle restriction due to GO, whereas TBII assay would be sufficient for evaluation of patients with proptosis.
Adult
;
Animals
;
Autoantibodies/*blood
;
CHO Cells
;
Cricetulus
;
Cross-Sectional Studies
;
Female
;
Graves Ophthalmopathy/blood/*etiology/*immunology
;
Humans
;
Immunoassay/*methods
;
Male
;
Middle Aged
;
Receptors, Thyrotropin/blood/*immunology
2.Development of Thyroid-Associated Ophthalmopathy in Patients Who Underwent Total Thyroidectomy.
Sun Young JANG ; Ka Hyun LEE ; Jong Rok OH ; Bo Yeon KIM ; Jin Sook YOON
Yonsei Medical Journal 2015;56(5):1389-1394
PURPOSE: To report clinical characteristics of thyroid-associated ophthalmopathy (TAO) in patients who previously underwent total thyroidectomy for thyroid cancer or a benign mass of the thyroid. MATERIALS AND METHODS: Of the patients who were diagnosed with TAO from March 2008 to March 2012, we performed a retrospective chart review on those who had undergone total thyroidectomy for thyroid cancer or a benign mass of the thyroid before the occurrence of ophthalmopathy. RESULTS: Of the 206 patients diagnosed with TAO, seven (3.4%) met the inclusion criteria. The mean age of the subjects was 47.4 years, and all were female. Six patients were diagnosed with papillary thyroid cancer, and one was diagnosed with a benign mass. The duration between total thyroidectomy and onset of TAO ranged from 3-120 months (median 48 months). Ophthalmic manifestations varied among cases. Except for the patient who was diagnosed with a benign mass, all patients showed hyperthyroid status and were under Synthroid hormone treatment at the time of TAO development. Five of these six patients had positive levels of thyroid-stimulating hormone (TSH) receptor autoantibodies. CONCLUSION: TAO rarely develops after total thyroidectomy, and the mechanism of TAO occurrence is unclear. However, most patients showed abnormalities in thyroid function and TSH receptor autoantibodies.
Adult
;
Aged
;
Autoantibodies/blood
;
Carcinoma
;
Carcinoma, Papillary/immunology/surgery
;
Female
;
Graves Ophthalmopathy/*diagnosis/immunology
;
Humans
;
Male
;
Middle Aged
;
Postoperative Complications/etiology/immunology/pathology
;
Receptors, Thyrotropin
;
Retrospective Studies
;
Thyroid Neoplasms/complications/*surgery
;
Thyroidectomy/adverse effects/*methods
;
Thyrotropin/blood
;
Treatment Outcome